Hubei Biocause Pharmaceutical (000627.SZ) subsidiary CHINA BEST life insurance company's accumulated premium income from January to August reached approximately 29.03 billion yuan.

17/09/2024

Tianmao Group (000627.SZ) has announced that its subsidiary, Guohua Life Insurance Co., Ltd., a company controlled by the company, will follow according to...

Hubei Biocause Pharmaceutical (000627.SZ) announces that its controlling subsidiary, CHINA BEST Life Insurance Co., Ltd., is proceeding with business development in accordance with the overall strategy of "firmly transitioning for development, highlighting value growth, comprehensively improving capabilities, and moving towards a mature insurance enterprise". The company is focusing on value-based business, continuously promoting business structure optimization. From January 1, 2024 to August 31, 2024, the accumulated original insurance premium income is approximately 29.03 billion yuan.

GREAT CHI HLDGS (00021): Wong Man Hei appointed as a new member of the nomination committee

Shandong Sito Bio-technology (300583.SZ): The chemical raw material drug budenide passed the drug GMP compliance inspection.

CH AGRI-PROD EX (00149) releases annual performance, with a net profit attributable to shareholders of 7.8 million Hong Kong dollars, an increase of 5.4% year-on-year.

GREAT CHI HLDGS (00021): Wong Man Hei appointed as a new member of the nomination committee

Shandong Sito Bio-technology (300583.SZ): The chemical raw material drug budenide passed the drug GMP compliance inspection.

CH AGRI-PROD EX (00149) releases annual performance, with a net profit attributable to shareholders of 7.8 million Hong Kong dollars, an increase of 5.4% year-on-year.